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Opinion statement
Systemic therapy is the only treatment option for the majority of mesothelioma
patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and
locally advanced disease often preclude surgery. For many years, chemotherapy had a
minimal impact on the natural history of this cancer, engendering considerable
nihilism. Countless drugs were evaluated, most of which achieved response rates below
20% and median survival of<1 year. Several factors have hampered the evaluation of
systemic regimens in patients with mesothelioma. The disease is uncommon, affecting
only about 2500 Americans annually. Thus, most clinical trials are small, and ran-
domized studies are challenging to accrue. There is significant heterogeneity within
the patient populations of these small trials, for several reasons. Since all of the
staging systems for mesothelioma are surgically based, it is almost impossible to
accurately determine the stage of a patient who has not been resected. Patients with
very early stage disease may be lumped together with far more advanced patients in
the same study. The disease itself is heterogenous, with many different prognostic
factors, most notably three pathologic subtypes—epithelial, sarcomatoid, and
biphasic—that have different natural histories, and varying responses to treatment.
Finally, response assessment is problematic, since pleural-based lesions are difficult to
measure accurately and reproducibly. Assessment criteria often vary between trials,
making some cross-trial comparisons difficult to interpret. Despite these limitations,
in recent years, there has been a surge of optimism regarding systemic treatment of
this disease. Several cytotoxic agents have been shown to generate reproducible
responses, improve quality of life, or prolong survival in mesothelioma. Drugs with
single-agent activity include pemetrexed, raltitrexed, vinorelbine, and vinflunine. The
addition of pemetrexed or raltitrexed to cisplatin prolongs survival. The addition of
cisplatin to pemetrexed, raltitrexed, gemcitabine, irinotecan, or vinorelbine improves
response rate. The combination of pemetrexed plus cisplatin is considered the
benchmark front-line regimen for this disease, based on a phase III trial in 456
patients that yielded a response rate of 41% and a median survival of 12.1 months.
Vitamin supplementation with folic acid is essential to decrease toxicity, though
recent data suggests that there may be an optimum dose of folic acid that should be
administered; higher doses may diminish the effectiveness of pemetrexed. There are
also several unresolved questions about the duration and timing of treatment with
pemetrexed that are the subject of planned clinical trials. It is essential to recognize
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that the improvements observed with the pemetrexed/cisplatin combination, though
real, are still modest. Other active drugs or drug combinations may be more appropriate
for specific individuals, and further research is still needed to improve upon these results.
Since the majority of mesotheliomas in the United States occur in the elderly, non-
cisplatin-containing pemetrexed combinations may be more appropriate for some
patients. Now that effective agents have been developed for initial treatment, several
classical cytotoxic drugs and many novel agents are being evaluated in the second-line
setting. These include drugs targeted against the epidermal growth factor, platelet-
derived growth factor, vascular endothelial growth factor, src kinase, histone deace-
tylase, the proteasome, and mesothelin. Given the progress made in recent years, there is
reason to believe that more effective treatments will continue to be developed.
Introduction
It was exactly 20 years ago that the Journal of Clinical
Oncology published an article entitled ‘‘Malignant
mesothelioma, a disease unaffected by current thera-
peutic maneuvers’’ [1]. That title aptly sums up the
profound sense of nihilism toward treatment for
mesothelioma that existed for many years. At that
time, chemotherapy truly had a minimal impact on
the natural history of this cancer. Countless drugs
were evaluated. Given the rarity of mesothelioma,
most trials were small, assessment criteria varied,
and few agents demonstrated meaningful activity.
Response rates were all under 20% and patients rarely
survived more than a year [2].
We have made a great deal of progress against this
disease in the ensuing years. New chemotherapy drugs
have now been shown to improve survival and quality
of life for patients with mesothelioma. This review
discusses the current treatment options for mesothe-
lioma, focusing on the most recent studies, as well as
on many of the novel agents undergoing assessment
in clinical trials.
Cytotoxic chemotherapy before pemetrexed
• The anthracyclines were once considered the ‘‘gold-standard’’ drugs
for mesothelioma. Before computed tomography was routinely used,
response rates of up to 44% were reported for doxorubicin [2, 3].
However, in the largest retrospective series, the Eastern Cooperative
Oncology Group documented a response rate of only 14% in 51
patients [4]. The data are similar for epirubicin [3]. Several liposomal
formulations and cardiac protectants have been evaluated to decrease
anthracycline-induced cardiac toxicity, but these are even less effective
[3, 5, 6].
• Three recent trials have combined epirubicin with either cisplatin or
gemcitabine. The European Lung Cancer Working Party (ELCWP)
observed a 19% response rate and a median survival of 13.3 months
in a phase II trial of epirubicin and cisplatin in 69 patients [7]. The
North Central Cancer Treatment Group evaluated 2 dose levels of the
combination of epirubicin and gemcitabine and reported response
rates of 13% and 7%, respectively, for the high-dose and low-dose
regimens. Moderately severe toxicity was observed in both treatment
groups [8]. Similarly, Italian researchers reported a 14% response rate
and a median survival of 55 weeks for epirubicin/gemcitabine in a
26-patient study [9]. None of these combinations are significantly
better than the more recent gemcitabine- or antifolate-based regimens,
thus, none are being pursued further.
• A meta-analysis of clinical trials from 1965 to 2001 determined that
cisplatin was the most active single agent in mesothelioma [10•].
Carboplatin has similar activity [10•]. Oxaliplatin has been studied in
combination with raltitrexed, vinorelbine, and gemcitabine, but has
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not been evaluated as a single agent in this disease [3]. The platinum
analog ZD0473 demonstrated no activity in a phase II trial in 41
previously treated mesothelioma patients [11].
• Although paclitaxel, docetaxel, and irinotecan inhibit mesothelioma
growth in preclinical models, these drugs have no single-agent activity
in mesothelioma patients [2, 3, 12]. Phase II studies of irinotecan plus
cisplatin with or without mitomycin C suggest that irinotecan may
have activity in combination with cisplatin [3, 13].
The antifolates
• The antifolates are the most active class of cytotoxic drugs for meso-
thelioma. In a 60-patient trial, high-dose methotrexate yielded a 37%
response rate and a median survival of 11 months [14]. The Cancer and
Leukemia Group B (CALGB) reported a response rate of 25% and sig-
nificant toxicity in a phase II trial of edatrexate; both response and
toxicity were decreased by the addition of leucovorin [15]. More
recently, the novel antifolate pralatrexate demonstrated activity in pre-
clinical models, but not in a phase II trial in mesothelioma patients [16].
• The only FDA-approved agent for mesothelioma is pemetrexed, an
antifolate which principally targets thymidylate synthase, as well as
dihydrofolate reductase and glycinamide ribonucleotide formyltrans-
ferase. Pemetrexed may be more active in mesothelioma than in other
cancers because of a high capacity cell membrane transporter in
mesothelioma which is highly specific for pemetrexed [17].
• The activity of single-agent pemetrexed is similar to many other drugs
in this disease. A 64-patient phase II trial of pemetrexed demonstrated
a partial response rate of 14%, a median time to progression of
4.7 months, and a median overall survival of 10.7 months [18].
Pemetrexed was approved by the Food and Drug Administration
(FDA) based on a 456 patient, single-blind, placebo-controlled, phase
III study. Patients were randomized to pemetrexed, 500 mg/m2 every
21 days and cisplatin 75 mg/m2, or placebo and cisplatin [19••]. The
response rate for the combination was significantly greater than for
single-agent cisplatin (41% vs 17%; P < 0.001). Pemetrexed/cisplatin-
treated patients had a median survival of 12.1 months, compared
with 9.3 months for patients treated with cisplatin alone (P = 0.020).
Time to progression was also superior (5.7 vs 3.9 months, P = 0.001).
In addition, treatment with this combination resulted in a significant
improvement in pulmonary function, quality of life, and symptoms
such as pain and dyspnea.
• After the first 117 patients enrolled in this study, all patients were
supplemented with dietary doses of folate and vitamin B12. Vitamin
supplementation improved response rates and survival in both treat-
ment arms, and reduced the incidence of serious toxicity. In preclin-
ical models, there is a very significant decrease in pemetrexed activity
as the extracellular folate level increases above the physiologic range.
This suggests that it may be appropriate to limit folate supplementa-
tion to no more than 400 lg, the amount found in a multivitamin,
rather than the 1000 lg that is more frequently prescribed [20•].
• In the United States, mesothelioma is a disease of the older patient,
with a median age of onset of 74 years [21]. Since elderly mesothe-
lioma patients with co-morbid illnesses may not be able to tolerate
cisplatin, the better-tolerated carboplatin is frequently substituted; the
two regimens have comparable activity. A similar time to progression
(6.5 months) and overall survival (12.7 months) was observed in a
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102-patient phase II trial of pemetrexed plus carboplatin as in the
phase III trial of pemetrexed-cisplatin [22]. A 76-patient phase II study
reported a time to progression of 8.0 months, a median survival of
14 months, and a response rate of 25% using the same regimen [23].
A retrospective subset analysis of these two trials reported similar
outcomes with pemetrexed-carboplatin in elderly patients compared
with younger individuals, with the exception of greater hematologic
toxicity in the older patients [24].
• There are several unresolved questions regarding timing and duration
of pemetrexed treatment. Some epithelial mesothelioma patients may
have prolonged stable disease for months or even years without
chemotherapy. It is not known whether these patients should be
treated at diagnosis, at symptom progression, or at radiographic
progression. In a very small pilot study from the Royal Marsden
Hospital, there was a trend toward a longer time to symptomatic
progression and overall survival in those patients who received che-
motherapy at diagnosis rather than at symptom progression [25];
however, these results need to be validated in a larger study with a
more active chemotherapy regimen than was employed in that study.
We also do not know the optimum length of treatment. Most patients
receive between 4 and 8 cycles of pemetrexed with cis- or carboplatin,
few can tolerate more. Should they stop treatment at that point, or
continue with single-agent pemetrexed? A small, non-randomized
Dutch feasibility study of pemetrexed maintenance demonstrated that
maintenance is well tolerated, and that responses can occur after six
cycles of treatment [26]. The CALGB is currently designing a larger,
randomized study to more definitively address this question.
• Pemetrexed is not the only antifolate which has activity in mesotheli-
oma. The European Organization for the Research and Treatment of
Cancer and the National Cancer Institute of Canada performed a 250-
patient, randomized phase III trial of raltitrexed-cisplatin vs cisplatin.
No vitamin supplementation was given. The combination achieved a
response rate of 24% and a median survival of 11.2 months, compared
with 14% and 8.8 months for cisplatin. The P values were of borderline
significance, likely because the study was underpowered [27].
Other active cytotoxic agents
• Although gemcitabine has limited single-agent activity in this disease,
response rates ranging from 12% to 48% have been reported for the
gemcitabine/cisplatin combination [28–30]. These differences in
activity likely reflect the heterogeneity in patient selection and incon-
sistency in response assessment between trials, rather than the slightly
different schedules of these regimens. As an example, in the initial study,
Byrne and colleagues administered gemcitabine 1000 mg/m2 on days 1,
8, and 15, and cisplatin 100 mg/m2 on day 1 of a 28-day schedule to 21
patients. They reported a partial response rate of 48%, a median survival
of 9.4 months, and symptom improvement in 90% of responding
patients [29]. These investigators then employed an identical regimen in
a 52-patient multicenter study, and noted a partial response rate of 33%
and a median survival of 11.2 months [28].
• Other gemcitabine doublets with activity in mesothelioma include
gemcitabine plus carboplatin, which achieved a 26% response rate
and a median survival of 15.1 months in a 50-patient trial [28], and
gemcitabine plus oxaliplatin, which produced a response rate of 40%
and a median survival of 13 months in a 25-patient study [31]. The
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combination of gemcitabine plus pemetrexed is no more active than
either agent alone, but has greater toxicity [32].
• Vinorelbine has one of the highest response rates of any single-agent
against mesothelioma, and recent phase III data suggest that it may
improve survival over best supportive care. A phase II trial of vino-
relbine, 30 mg/m2 weekly, in 29 patients reported partial responses in
24%, stable disease in 55%, and a median survival of 10.6 months.
Quality of life improved in 41% of patients, and pulmonary symp-
toms were better in 48% [33]. In a 63-patient trial in the second-line
setting, a response rate of 16% and a median survival of 9.6 months
were achieved [34]. The combination of vinorelbine with cisplatin
yielded a response rate of 29.6% and a median survival of
16.8 months [35].
• The phase III MS01 trial, from the Medical Research Council and
British Thoracic Society, randomized 409 newly diagnosed mesothe-
lioma patients to active symptom control (ASC) alone or with che-
motherapy (vinorelbine or mitomycin–vinblastine–cisplatin, MVP).
Pooled survival data for the two chemotherapy arms achieved bor-
derline significance in favor of chemotherapy (7.6 vs 8.5 months,
P = 0.32) compared with ASC. When analyzed by the type of che-
motherapy given, ASC and MVP resulted in similar survival (7.6 and
7.8 months, respectively), while the patients who received vinorelbine
lived a median of 9.4 months (HR 0.81, P = 0.11). Although the
study was not powered to detect a difference between chemotherapy
arms, one may infer that the addition of inactive chemotherapy
(MVP) does not improve survival or quality of life in mesothelioma
patients, while the addition of an active drug, such as vinorelbine,
may do so [36••].
• Vinorelbine is not the only vinca alkaloid which has activity in
mesothelioma. The novel vinca alkaloid, vinflunine, achieved a
response rate of 13.8% and a median survival of 10.8 months [37].
Despite this activity, the drug is not being developed further for
mesothelioma.
Novel agents
• Given the relative rarity of mesothelioma, a surprising number of
novel agents have been evaluated, including drugs targeted against the
epidermal growth factor, platelet derived growth factor, vascular
endothelial growth factor, src kinase, histone deacetylase, the pro-
teasome, and mesothelin.
• Despite preclinical data that suggested activity, the initial studies of
targeted agents were underwhelming. Although EGFR is highly over-
expressed in mesothelioma, and although the EGFR tyrosine kinase
inhibitor gefitinib inhibits mesothelioma in vitro, minimal activity was
observed in two phase II trials of gefitinib and in one trial of erlotinib
[38–40]. This may be explained, in part, by the rarity of EGFR
mutations in mesothelioma [41]. Similarly, preclinical data suggested
a key role for platelet-derived growth factor (PDGF) in mesothelioma,
yet imatinib, a selective inhibitor of the PDGF receptor tyrosine
kinase, failed to achieve any responses in 4 phase II trials [42].
• Vascular endothelial growth factor signaling may have an important
role in the biology of mesothelioma. High serum VEGF, a negative
prognostic factor in this disease, is inversely correlated with survival.
Phase II studies of SU5416, vatalanib, thalidomide, and sorafenib
have demonstrated only modest single agent activity, comparable to
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other single agents in this disease [42]. Vatalanib, an inhibitor of
PDGFR-b and all VEGFR tyrosine kinases, yielded an 11% response
rate, a 66% rate of stable disease, and a 10-month median survival in a
phase II CALGB trial [43]. Stable disease for longer than 6 months was
achieved in 27.5% of the 40 patients in a phase II Dutch study of
thalidomide [42]. On the basis of these data, the phase III NVALT 5
trial evaluates maintenance thalidomide after the completion of
pemetrexed-based chemotherapy. The CALGB studied sorafenib, an
inhibitor of VEGFR2, PDGFR-b, and raf kinase, in both chemo-naı¨ve
and previously treated patients. As a likely result of patient selection,
median survival in the chemo-naive patients was 5.2 months, com-
pared with 14.3 months for the patients who were previously treated
[44]. An ongoing study of sunitinib in previously treated patients
showed a 15% response rate by conventional CT scan, and a 30%
response rate by FDG-PET [45].
• The University of Chicago performed a double-blind, placebo-con-
trolled randomized phase II trial in 108 patients to evaluate the
addition of the anti-VEGF monoclonal antibody bevacizumab to
gemcitabine plus cisplatin [46]. Progression-free survival, the primary
endpoint, was 6.9 months for the bevacizumab arm and 6.0 months
for placebo (HR 0.93, P = 0.88). Median overall survival, for bev-
acizumab and placebo, respectively, was 15.6 and 14.7 months
(P = 0.91). Higher baseline plasma VEGF levels correlated with
shorter progression-free survival (P = 0.02) and overall survival
(P = 0.0066). Bevacizumab-treated patients with low baseline VEGF
levels had a longer overall survival. Several studies of bevacizumab in
combination with pemetrexed and platinum are ongoing.
• Src is very frequently expressed and activated in mesothelioma. Src
kinase activity is associated with advanced stage in mesothelioma and
may contribute to invasiveness and metastatic spread. Dasatinib, a
potent inhibitor of src family kinases, inhibits migration and invasion
of mesothelioma in preclinical models [47]. The CALGB is currently
testing dasatinib in previously treated patients.
• Suberoylanilide hydroxamic acid (SAHA), an oral inhibitor of class I
and II histone deacetylases, is a potent inhibitor of mesothelioma
growth in vitro. It is interesting that SAHA represses the gene for thy-
midylate synthase, the principal target of pemetrexed. In a phase I trial
of SAHA, there were two partial responses in the 13 mesothelioma
patients enrolled [48]. All patients with at least stable disease had a
decrease in dyspnea or pain. These data formed the basis of the
ongoing double-blind, placebo-controlled, randomized phase III
international trial in 660 previously treated patients. The primary
endpoint is overall survival.
• In preclinical mesothelioma models, the proteasome inhibitor bort-
ezomib inhibits constitutive activation of NFkB and enhances the
cytotoxicity of cisplatin and pemetrexed [49, 50]. Bortezomib, both as
a single agent and in combination with cisplatin, is being evaluated in
two European mesothelioma trials.
• Over 90% of mesotheliomas express mesothelin, a cell surface
glycoprotein found on normal mesothelial cells of the pleura,
peritoneum, and pericardium. Several agents with activity in preclinical
models are being developed to target mesothelin: a recombinant
immunotoxin, (SS1P), a humanized monoclonal antibody
(MORAb-009), and an attenuated listeria vector that encodes human
mesothelin (CRS-207). SS1P and Morab-009 have completed phase I
evaluation. Preclinical models have demonstrated significant synergy of
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these agents with cytotoxic chemotherapy, and trials that combine these
drugs with pemetrexed and cisplatin are in development [51•–54].
• In conclusion, it is clear that mesothelioma is no longer a disease that
inspires nihilism. Chemotherapy improves survival, response, and
quality of life in mesothelioma patients. Many novel agents are being
investigated, and further progress is eagerly awaited.
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